Noble Affirms BioCryst Pharma (BCRX) at 'Buy' Following Q4 Results; Two Oral HAE Programs Moving Forward

February 24, 2016 11:57 AM

Noble Financial affirms BioCryst Pharma (Nasdaq: BCRX) with a Buy rating and $8 price target after the company reported quarterly ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found